Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Lange, Falko ^a   Franz, Benjamin ^a   Maletzki, Claudia ^a   Linnebacher, Michael ^a   Hühns, Maja ^a   Jaster, Robert ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; CELL DNA; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FAS LIGAND; K RAS PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN FOS; PROTEIN P53; REGORAFENIB; TRAMETINIB; VEMURAFENIB; BROXURIDINE; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CASE REPORT; COLORECTAL CANCER; DNA CONTENT; DNA SYNTHESIS INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; CELL DEATH; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IC50; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GENE;

AGED; AGED, 80 AND OVER; BROMODEOXYURIDINE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84935914246     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/568693     Document Type: Article

References (39)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014, " CA: Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
2. Y.-D. Cheng, H. Yang, G.-Q. Chen, and Z.-C. Zhang, "Molecularly targeted drugs for metastatic colorectal cancer, " Drug Design, Development and Therapy, vol. 7, pp. 1315-1322, 2013.
3. S. M. Wilhelm, J. Dumas, L. Adnane, et al., "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity, " International Journal of Cancer, vol. 129, no. 1, pp. 245-255, 2011.
4. A. Grothey, E. Van Cutsem, A. Sobrero, et al., "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, " The Lancet, vol. 381, no. 9863, pp. 303-312, 2013.
5. T. Efferth, "Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules, " Current Medicinal Chemistry, vol. 19, no. 33, pp. 5735-5744, 2012.
6. E. Martinelli, T. Troiani, E. DAiuto, et al., "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or withmulti-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells, " International Journal of Cancer, vol. 133, no. 9, pp. 2089-2101, 2013.
7. S. Yoon and R. Seger, "The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions, " Growth Factors, vol. 24, no. 1, pp. 21-45, 2006.
8. C. Montagut and J. Settleman, "Targeting the RAF-MEK-ERK pathway in cancer therapy, " Cancer Letters, vol. 283, no. 2, pp. 125-134, 2009.
9. S. Ogino, J. A. Meyerhardt, N. Irahara, et al., "KRASmutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803, " Clinical Cancer Research, vol. 15, no. 23, pp. 7322-7329, 2009.
10. M. Brink, A. F. P. M. de Goeij, M. P. Weijenberg, et al., "Kras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study, " Carcinogenesis, vol. 24, no. 4, pp. 703-710, 2003.
11. H. Davies, G. R. Bignell, C. Cox, et al., "Mutations of the BRAF gene in human cancer, " Nature, vol. 417, no. 6892, pp. 949-954, 2002.
12. P. M. Wilson, M. J. LaBonte, and H.-J. Lenz, "Molecularmarkers in the treatment of metastatic colorectal cancer, " The Cancer Journal, vol. 16, no. 3, pp. 262-272, 2010.
13. K.-K. Wong, J. A. Engelman, and L. C. Cantley, "Targeting the PI3K signaling pathway in cancer, " Current Opinion in Genetics &Development, vol. 20, no. 1, pp. 87-90, 2010.
14. S. Ward, Y. Sotsios, J. Dowden, I. Bruce, and P. Finan, "Therapeutic potential of phosphoinositide 3-kinase inhibitors, " Chemistry & Biology, vol. 10, no. 3, pp. 207-213, 2003.
15. N. T. Ihle, G. Powis, and S. Kopetz, "PI-3-Kinase inhibitors in colorectal cancer, " Current Cancer Drug Targets, vol. 11, no. 2, pp. 190-198, 2011.
16. T. L. Yuan and L. C. Cantley, "PI3K pathway alterations in cancer: variations on a theme, " Oncogene, vol. 27, no. 41, pp. 5497-5510, 2008.
17. J. Tsai, J. T. Lee, W. Wang, et al., "Discoveryof a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 8, pp. 3041-3046, 2008.
18. A. G. Gilmartin, M. R. Bleam, A. Groy, et al., "GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition, " Clinical Cancer Research, vol. 17, no. 5, pp. 989-1000, 2011.
19. S. B. Kondapaka, S. S. Singh, G. P. Dasmahapatra, E. A. Sausville, and K. K. Roy, "Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation, "Molecular CancerTherapeutics, vol. 2, no. 11, pp. 1093-1103, 2003.
20. K. T. Flaherty, I. Puzanov, K. B. Kim, et al., "Inhibition of mutated, activated BRAF in metastatic melanoma, " The New England Journal of Medicine, vol. 363, no. 9, pp. 809-819, 2010.
21. S. Kopetz, J. Desai, E. Chan, et al., "PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors, " Journal of Clinical Oncology, vol. 28, supplement, abstract 3534, no. 15, 2010.
22. R. B. Corcoran, H. Ebi, A. B. Turke, et al., "EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib, " Cancer Discovery, vol. 2, no. 3, pp. 227-235, 2012.
23. M. Mao, F. Tian, J. M. Mariadason, et al., "Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents, " Clinical Cancer Research, vol. 19, no. 3, pp. 657-667, 2013.
24. T. Yamaguchi, R. Kakefuda, N. Tajima, Y. Sowa, and T. Sakai, "Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo, " International Journal of Oncology, vol. 39, no. 1, pp. 23-31, 2011.
25. M. Watanabe, Y. Sowa, M. Yogosawa, and T. Sakai, "Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells, " Cancer Science, vol. 104, no. 6, pp. 687-693, 2013.
26. J. C. Bendell, J. Nemunaitis, S. J. Vukelja, et al., "Randomized placebo-controlled phase II trial of perifosine, plus capecitabine as second-or third-line therapy in patients with metastatic colorectal cancer, " Journal of Clinical Oncology, vol. 29, no. 33, pp. 4394-4400, 2011.
27. J. C. Bendell, T. Ervin, N. Senzer, et al., "Results of the XPECT study: a phase III randomized double-blind, placebocontrolled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC), " Journal of Clinical Oncology, vol. 30, 2012.
28. M. B. Chen, X. Y. Wu, G. Q. Tao, et al., "Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro, " International Journal of Cancer, vol. 131, no. 11, pp. 2487-2498, 2012.
29. M. Linnebacher, C. Maletzki, C. Ostwald, et al., "Cryopreservation of human colorectal carcinomas prior to xenografting, " BMC Cancer, vol. 10, article 362, 2010.
30. C. Maletzki, S. Stier, U. Gruenert, et al., "Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas, " PLoS ONE, vol. 7, no. 12, Article IDe52485, 2012.
31. B. S. Danes, P. Deangelis, F. Traganos, M. R. Melamed, and T. Alm, "Demonstration of altered cellular DNA content distribution in long-term colon epithelial cell lines with colon cancer genotypes, " Scand inavian Journal of Gastroenterology, vol. 23, no. 7, pp. 840-846, 1988.
32. J. Bocsi and A. Zalatnai, "Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability inmorphology, DNA ploidy and proliferation activity, " Journal of Cancer Research and Clinical Oncology, vol. 125, no. 1, pp. 9-19, 1999.
33. S. Kang, A. G. Bader, and P. K. Vogt, "Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 802-807, 2005.
34. F. Lange, K. Rateitschak, C. Kossow, O. Wolkenhauer, and R. Jaster, "Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach, " World Journal of Gastroenterology, vol. 18, no. 43, pp. 6226-6234, 2012.
35. F. Lange, K. Rateitschak, B. Fitzner, R. Pohland, O. Wolkenhauer, and R. Jaster, "Studies on mechanisms of interferongamma action in pancreatic cancer using a data-driven and model-based approach, " Molecular Cancer, vol. 10, article 13, 2011.
36. H. Kamiyama, S. Rauenzahn, J. S. Shim, et al., "Personalized chemotherapy prof iling using cancer cell lines from selectable mice, " Clinical Cancer Research, vol. 19, no. 5, pp. 1139-1146, 2013.
37. B. Vecsey-Semjen, K.-F. Becker, A. Sinski, et al., "Novel colon cancer cell lines leading to better understand ing of the diversity of respective primary cancers, " Oncogene, vol. 21, no. 30, pp. 4646-4662, 2002.
38. E. Tulchinsky, "Fos family members: regulation, structure and role in oncogenic transformation, " Histology and Histopathology, vol. 15, no. 3, pp. 921-928, 2000.
39. K. T. Flaherty, J. R. Infante, A. Daudet al., "CombinedBRAFand MEK inhibition inmelanoma with BRAF V600mutations, " The New England Journal of Medicine, vol. 367, no. 18, pp. 1694-1703, 2012.